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EDITORIAL REVIEW
Determinants of ureagenesis, with particular reference to
renal failure
Urea production and degradation
(1) Urea production versus urea appearance.
Production or generation of urea includes an impor-
tant moiety derived from the enterohepatic circula-
tion of urea nitrogen, urea —* ammonia —p urea. This
cycle does not result in any loss of nitrogen from the
body. In contrast, when nitrogen derived from en-
dogenous and exogenous protein is irreversibly
converted to urea, it appears as such in urine and
body fluids. Thus, the difference between urea pro-
duction and recycled or metabolized urea has been
termed urea appearance (or "net production").
This quantity, rather than total urea production, is
one of the determinants of nitrogen balance (see be-
low).
In normal subjects, urea appearance is usually
equal to urea excretion. Steady-state blood urea
concentration obviously varies with steady-state
urea output. In renal failure, however, urea may ac-
cumulate progressively, or, when renal function im-
proves, the body urea pool may diminish signifi-
cantly. In anuria, accumulation obviously becomes
equal to appearance. These considerations under-
score why the definition of urea appearance must
include both urea excretion and accumulation,
whether the latter is a positive or negative quantity.
The time course of the response in the size of the
urea pooi (and thus in blood urea concentration) to
a step change in the rate of urea appearance (as, for
example, when protein intake is changed) depends
upon the turnover time of the pooi. In normal sub-
jects, the turnover time is measured in hours, so
that blood urea concentration responds quite rapid-
ly to a change in urea appearance. In renal failure,
however, the turnover time is greatly prolonged and
is measured in days. Consequently, a step change in
urea appearance produces a progressive change in
blood urea that approaches a new limiting value
with a half-time that may be as long as a week.
Hence accumulation, whether positive or negative,
is quite commonly a significant fraction of total ap-
pearance in such patients, and thus may significant-
ly affect nitrogen balance measurements.
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It is worth noting that, even in subjects with nor-
mal renal function, excretion may differ from ap-
pearance owing to changes in the urea pool. For ex-
ample, several studies have documented the decline
in urea excretion that follows the onset of fasting or
ingestion of a protein-free diet [1, 2]. The declining
curve of urea excretion under such circumstances is
usually taken as an accurate reflection of the rate
of fall of net urea production. Actually, appear-
ance falls much faster than these curves would sug-
gest because the urea pool is decreasing, and hence
urea accumulation is a negative quantity. Another
source of error is the accumulation that occurs on
i.v. amino acid loading. Under these circumstances,
ignoring urea accumulation (as well as accumula-
tion of amino acids themselves) makes nitrogen bal-
ance seem more positive than it is. Finally, accurate
measurement of urea accumulation becomes the
limiting factor in assessing hour-to-hour changes in
urea appearance in normal subjects fed high-nitro-
gen loads. In one such study, Rafoth and Onstad [3]
showed that normal human subjects could produce
at least 50 mg of urea per kilogram of lean body
mass per hour, with no evidence of a plateau being
reached. As they note, earlier work [4], in which a
maximal rate of urea synthesis in normal subjects
was purportedly demonstrated, suffered from de-
fects in experimental design such that synthesis ap-
peared to reach a plateau before it was in fact maxi-
mal.
Precise measurement of accumulation requires
knowledge of the urea space, for example, by iso-
topic urea dilution or other techniques for measur-
ing total body water. This, however, is seldom nec-
essary. An assumed urea space of 60% of body
weight will suffice for most purposes, provided that
changes in body weight are also taken into account.
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Obviously, water retention can reduce serum urea
nitrogen by increasing urea space without changing
its total urea content, that is, the urea pool.
Changes in body weight, in the short term, can be
equated with changes in body water. Thus, the esti-
mated urea space on any given day during a short-
term study can be assumed to have changed by the
same number of liters as body weight (in kilograms)
has changed. This is tantamount to assuming that
weight minus urea space, or "nonurea space," re-
mains constant. "Nonurea space" is thus an esti-
mate of total body solids, including fat.
A technique for measuring urea appearance in pa-
tients undergoing regular hemodialysis has recently
been reported [5]. Measurements of serum urea ni-
trogen before and after dialysis and on the days be-
tween dialyses, combined with measurements of 24-
hr urine urea excretion on these days (in patients
with kidneys) can be analyzed mathematically to
yield urea appearance rate (not "urea generation
rate," as the authors state). The technique is a use-
ful adjunct in the management of dialysis patients,
especially as a check on dietary protein intake.
(2) Urea degradation. Several authors have mea-
sured urea degradation by the following technique.
Labeled urea is injected i.v. and the decline in spe-
cific activity of circulating urea is observed. Extrap-
olation of the exponential decay back to the time of
injection, with certain corrections [6], yields the
urea space and urea pool. The product of the pool
and the decay constant then gives production rate,
assuming that the system can be treated as a single
pool. Production rate can then be compared with
excretion rate to give an estimate of urea degrada-
tion. Results of such measurements in normal sub-
jects are summarized in Table 1.
This widely used isotopic technique for measur-
ing production rate of various metabolites has a pit-
fall that is often overlooked, and it has been uni-
formly overlooked in the case of urea. As pointed
out by Shipley and Clark [13], "one's ability to
draw a straight line through the terminal points of
observed data plotted on semilog paper is not, per
Se, justification for treating the system as a single
pool." When earlier points are obtained and the
curve of disappearance of labeled material is ana-
lyzed, another exponential component with a sub-
stantial intercept may be found, indicating at least a
two-pool system. Estimates of pool size and decay
constant may both be considerably in error under
these circumstances. The magnitude of the error de-
pends on the relative sizes of the two pools and the
relative values of the two rate constants, as ex-
plained by these authors [13].
Table 1. Urea metabolism in norma! human subjects
Extrarenal
Reference
No. of
subjects
Degradation
g N/day
clearance
liters/day
Walser and Bodenlos, 1959 [6] 3 3.5 14
Jones eta!, 1969[7] 2 3.4 19
Murdaugh,1970[8] 2 2.6 36
Walser and DIab!, 1974 [9] 6 4.9 27
Varcoeetal,1975[IO] 6 1.5 18
Gibsonetal, 1976[1l]
4ogprotein 6 2.9 31
lOOgprotein 6 5.1 31
Longetal,1978{12] 3 3.2 22
In the case of labeled urea, only meager observa-
tions obtained earlier than 1 hour after injection
have been reported [12—14], but it appears that the
earlier component of the decay curve has t'/2 of 10
to 15 mm and an intercept similar in magnitude to
the intercept of the later, slow component, whose
t'/2 is about 6 hr. Presumably, this faster component
represents equilibration of extracellular urea with
intracellular urea. If these estimates are correct, the
degree of overestimation of urea space and urea
production in published data is probably small. In
renal failure (see below), this error would clearly be
negligible because the half-life of the slow com-
ponent is so prolonged.
In normal subjects, reported data indicate that
about one quarter of the urea produced in the liver
is hydrolyzed by bacterial urease in the gastrointes-
tinal tract to ammonia and carbon dioxide (Table 1).
This amounts to the formation of about 3.6 g of am-
monia nitrogen per day, all of which is converted
back to urea in the liver. Expressed in clearance
terms, extrarenal clearance of urea nitrogen is 3.6 g/
day divided by 0.15 g/liter, or about 24 liters/day. A
small fraction of this extrarenal clearance may be
attributable to urea excretion by extrarenal routes
such as sweat, especially in uremic subjects [16],
but clearly urea degradation accounts for most of it.
Fecal urea is negligible, even in uremia [17].
In chronic renal failure, the amount of urea nitro-
gen converted to ammonia nitrogen per day is usu-
ally similar to the amount converted in normal sub-
jects (Fig. 1) [21]. This is difficult to understand, be-
cause urea concentration in body fluids is increased
many times, and furthermore, there appears to be
an adaptive increase in the urease activity of bowel
contents in patients with chronic uremia [22]. On
the other hand, there is some evidence that high
urea concentrations inhibit bacterial urease [23].
Measurements of urea degradation in acute renal
failure have apparently not been reported.
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Fig. 1. Reported observations of extrarenal clearance versus re-
nal clearance of urea in patients with chronic uremia. The re-
suits of Robson (1964) [18], Walser (1974) [104], Varcoe et al
(1975) [10], and Mitch et a! (1977) [20] all show extrarenal clear-
ances under 10 liters/day (normal = 24 liter/day). One measure-
ment by Walser (1970) [19], shown as a closed triangle, and two
observations by Jones et al (1969) [7], shown as open squares, lie
far above the rest of these observations. No correlation between
extrarenal clearance and renal clearance of urea can be detected
in the other 60 observations. (Reprinted by permission of the au-
thor and W13 Saunders [21])
Although the absolute rate of degradation of urea
is unaltered in chronic renal failure, the fraction de-
graded may be greatly increased, to as much as
80%. This is because renal clearance is reduced
even more than is extrarenal clearance, so that the
latter quantity becomes a larger fraction of total
clearance.
(3) Induced changes in urea degradation. Aug-
mentation of urea degradation, for example, by ad-
ministration of urease, could be useful in renal fail-
ure if ammonia nitrogen could be used to synthesize
amino acids. In theory, such augmentation could al-
so lower blood urea. An example is shown in Fig. 2,
in which mice were injected i.p. with increasing
doses of microencapsulated urease. As urea degra-
dation increased, urea synthesis reached its maxi-
mal capacity, and further degradation progressively
reduced serum urea nitrogen. Obviously, this meth-
od of lowering blood urea can only result in progres-
sive accumulation of urea precursors, including am-
monia, as has been observed by Visek [24].
Another way to increase urea degradation now
under study is the combination of microencapsu-
lated urease with an ammonia-trapping substance,
administered orally [25]. In this manner, fecal ni-
trogen can be increased and blood urea reduced.
Whether this measure alone would be generally
useful in the treatment of uremia is doubtful. Al-
though the symptoms of uremia are correlated well
with serum urea nitrogen, this is probably because
the serum urea nitrogen is a reflection of the rate
of protein catabolism. Studies in which urea has
been added to the dialysis bath during hemodialy-
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Fig. 2. Reduction of serum urea by urease injection. Mice were
injected i.p. with 0, 1, 5, or 23 U of microencapsulated urease.
One hour later, 14CO2 content of expired air was then measured
continuously for 1.5 hr by placing the mice in chambers through
which air was drawn into an ethanolamine trap. Rates of urea
production and degradation were calculated from these data.
Mean values 1 SEM are shown. In untreated animals, urea deg-
radation averaged 24% of production. With increasing doses of
urease, urea degradation rises and serum urea falls progressive-
ly. (Walser M, unpublished observations)
sis have shown that a variety of symptoms begin
to appear as serum urea nitrogen rises above 150
to 200 mg/dl [26]. Whether these symptoms are cor-
related with changes in blood ammonia or are pre-
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vented by suppressing urea degradation has not
been determined. Furthermore, it has not been
demonstrated that reducing serum urea nitrogen
without changing protein degradation or renal func-
tion has any beneficial effect in uremia. Thus, the
use of measures directed exclusively at reducing
serum urea nitrogen, such as augmenting the excre-
tion of nitrogen in other forms, are not likely to be
helpful unless blood urea is very high.
Suppression of urea degradation by the oral ad-
ministration of poorly absorbed antibiotics does not
affect urea appearance [20]. It does, however, im-
prove nitrogen balance significantly [27], possibly
by reducing that portion of fecal nitrogen excretion
attributable to bacterial nitrogen. The effect is simi-
lar to the known effect of antibiotics in improving
growth and nitrogen balance in animals [28-31] as
well as in children [32—34] and in adults undergoing
physical training [35].
(4) Urea nitrogen reutilization. It was previously
assumed that chronic uremic patients on low-pro-
tein diets could reutilize urea nitrogen for protein
synthesis [36, 37]. Recent results show, however,
that nearly all of the ammonia nitrogen derived from
urea production is simply converted back to urea
[10. 20]. In contrast, normal subjects receiving diets
limiting in total nitrogen content can unquestion-
ably utilize some urea nitrogen [38—40]. Thus, it is
possible that uremic patients on diets adequate in
essential amino acid carbon skeletons but deficient
in total nitrogen may be able to reutilize urea nitro-
gen. As yet, this has not been convincingly demon-
strated.
Determinants of urea appearance
(1) Hepatic regulation of urea appearance: (a)
Substrates. One of the nitrogen atoms of urea is de-
rived from ammonia (via carbamyl phosphate syn-
thetase I) and the other from aspartate (via arginino-
succinic acid synthetase) (Fig. 3). The concept that
the function of the cycle is to detoxify ammonia is
doubtless an oversimplification. Although it is true
that high concentrations of ammonia are toxic, es-
pecially in the brain, ammonia subserves many im-
portant roles in metabolism [41], and is furthermore
nearly in equilibrium with other labile nitrogenous
compounds such as aspartate, glutamine, and gluta-
mate. Thus, it would be more appropriate to de-
scribe the function of the urea cycle as the removal
of excess labile nitrogen.
One source of ammonia for carbamyl phosphate
synthesis is the ammonia brought to the liver by the
portal vein. The ammonia concentration difference
between portal vein and hepatic vein in fasting man
is reported to be 0.12 mrt [42]. Multiplying this val-
ue by an average value of portal blood flow of 1.2
liters/mm [43] yields an average hepatic ammonia
uptake of 0.2 moles/day or 2.8 g of nitrogen per day,
or about 30% of normal urea production. Much of
this portal ammonia is derived from urea degrada-
tion, as shown in Table 1; another significant moiety
is derived from the conversion of glutamine nitro-
gen to ammonia nitrogen by the small bowel mu-
cosa [44, 45].
Most of the ammonia incorporated into carbamyl
phosphate is derived from amino acids, whether
these are transported to the liver via the portal vein
or are derived from proteolysis within the liver. An
additional source—the deamination of adenosine
monophosphate via the purine nucleotide cycle
[46]—is probably a minor pathway [47]. The imme-
diate precursor of most of the ammonia incorporat-
ed into carbamyl phosphate is almost certainly
glutamate [47], formed by transamination from oth-
er amino acids. Although some amino acids can
give rise to ammonia more or less directly, such as
glutamine, asparagine, serine, threonine, and histi-
dine, their rates of hepatic uptake are relatively
low. Thus, glutamate dehydrogenase in the liver
functions to provide most of the ammonia for carba-
my! phosphate synthesis, contrary to the earlier
suggestion [48] that this enzyme functions chiefly to
synthesize glutamate.
Aspartate is largely synthesized intramitochon-
drially [49], by transamination between glutamate
and oxaloacetate. The equality between utilization
of ammonia and aspartate required for urea syn-
thesis in the steady state is probably regulated by
substrate control. Thus, it proceeds by mass ac-
tion effects rather than a directly coupled mechanism
regulating the production of these two precursors.
Indirect coupling may occur through glutamate,
which serves as a precursor for both ammonia and
aspartate.
(b) Short-term regulation of urea genesis. Recent
studies in rats injected i.p. with complete mixtures
of amino acids have demonstrated a mechanism
whereby ureagenesis is rapidly activated following
protein loads [50]. Hepatic N-acetyl glutamate, an
activator of mitochondrial carbamyl phosphate syn-
thetase, rose up to fivefold within minutes in these
studies and induced an equally rapid fivefold activa-
tion of carbamyl phosphate synthetase activity, as
measured in intact mitochondria isolated from the
livers of these animals. At doses of amino acids
above 2 g/kg, no further activation occurred, and
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carbamyl phosphate synthetase activity reached the
same level as seen in disrupted mitochondria ex-
posed to optimal concentrations of N-acetyl gluta-
mate. Furthermore, little increase in blood am-
monia was seen with doses of 2 g/kg or less, where-
as hyperammonemia supervened at larger doses.
The mechanism of the rapid increase in N-acetyl
glutamate was evidently a substrate effect on the
enzyme N-acetyl glutamate synthetase induced by
glutamate, which also rose in the liver within min-
utes after the injection of amino acids. These results
suggest that ureagenesis is subject to rapid autoreg-
ulation.
Furthermore, when this N-acetyl-glutamate-medi-
ated mechanism is incapacitated by injection of
large doses of propionate (which reduce N-acetyl
glutamate in the liver and attenuate its response to
injected amino acids), hyperammonemia, especially
after injection of amino acids, is seen [51].
(c) Urea cycle enzymes. Several studies have
documented abnormalities in one or more of the en-
Arginino-
Succinate
4
Fumarate
zymes involved in urea synthesis in animals with
acute or chronic renal failure (Table 2). Although it
is often inferred that a change in urea cycle enzyme
activity would bring about a change in the steady-
state rate of urea synthesis, this is probably an over-
simplification, because the urea cycle normally op-
erates far below its maximal velocity. Consequent-
ly, changes in the activity of enzymes that are not
rate-limiting may have little effect, except tran-
siently. Even profound reduction in the activi-
ties of these enzymes may fail to alter the steady-
state rate of urea synthesis, because accumulation
of the intermediate proximal to the metabolic block
may compensate for the enzyme lack. This has been
shown both by mathematic modeling of the urea
cycle [58] and by the study of patients with severe
but partial defects of one of these enzymes [59].
From these considerations, it would seem that
the mild abnormalities of urea cycle enzymes listed
in Table 2 would have little or no effect on the
steady-state rate of ureagenesis in uremia, although
Table 2. Tissue levels of enzymes involved in urea synthesis in experimental uremia, expressed as percent of controlsa
In liver In kidney
[54][53] [54] [55] [56] [57]
Carbamyl phosphate synthetase
Ornithine transcarbamylase
Argininosuccinate synthetase
Argininosuccinate lyase
Arginase
Ornithine aminotransferase
129b
75
NS
NS
NS
71
NS
75
NS
200 73
74
42b
a All values shown are statistically significantly different from control except where denoted by NS (not significant). Brackets enclose
Reference number.
b Measured as combined activity of argininosuccinate synthetase and lyase.
Glutamate
N-acetyl glutamate
Aspartate
Citrulline
Proline
Glutamate 7
Ornithine
Arginine
Urea
Fig. 3. Diagram of the urea cycle and related pathways. The numbered enzymes are (1) carbamyl phosphate synthetase, 2) ornithine
transcarbamylase, (3) argininosuccinate synthetase, (4) argininosuccinate lyase, (5) arginase, (6) N-acetyl-glutamate synthetase, (7) orni-
thine aminotransferase, Al-pyrroline-5-carboxylate dehydrogenase, and l-pyrroline-5-carboxylate reductase (shown collectively).
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accumulation of urea cycle intermediates might oc-
cur to some degree.
(c) Urea cycle intermediates. Citriilline is re-
leased by the isolated perfused liver [60] and by the
splanchnic bed in normal man in the postabsorptive
state [61, 62]. Indirect evidence has been presented
that the kidney normally extracts, from the arterial
blood, citrulline made in the liver and converts it to
arginine [60, 62].
Citrulline is markedly increased in the plasma of
uremic patients and experimental animals [54, 64].
Diminution in the renal uptake of citrulline, owing
to renal impairment, is held to account for this find-
ing [53]. This hypothesis would require, however,
that the kidney normally takes up citrulline and re-
leases arginine, and available data [65] indicate that
the kidney takes up both amino acids to the same
extent. Furthermore, the intake of arginine, like
other amino acids, is generally far in excess of the
amounts required for protein synthesis, so that ca-
tabolism of arginine must be far more common than
a requirement for arginine synthesis. The only sig-
nificant pathway for metabolism of arginine is to or-
nithine, with ornithine then being degraded by orni-
thine aminotransferase. Thus, the mean daily flux
through the major path of ornithine metabolism in
the liver must be in the direction of ornithine catab-
olism rather than in the direction of de novo orni-
thine synthesis—which would be necessary for net
24-hr release of citrulline from the liver to be a posi-
tive quantity.
Another possible explanation of the hyper-
citrullinemia of uremia is decreased activity of argi-
ninosuccinate synthetase. When there is an inher-
ited lack of this enzyme, plasma citrulline concen-
trations increase as high as 3 or 4 mM [66]. By
mathematic modelling, it appears that a tenfold in-
crease in the Michaelis constant (Km) of this en-
zyme for citrulline would augment liver citrulline
concentration about 80% [58]. Neither liver citrul-
line concentration nor liver argininosuccinate syn-
thetase activity, however, appear to be abnormal in
experimental uremia (see below). Thus, the hyper-
citrullinemia of uremia remains an unsolved problem.
Plasma ornithine is variably reported to be de-
creased, normal, or increased in chronic renal fail-
ure; plasma arginine is usually found to be normal
or somewhat decreased [21]. Intracellular ornithine
has not been reported in human liver, but in muscle
of uremic patients, ornithine is markedly reduced
[67]. In rats, hepatic ornithine, citrulline, and argi-
nine concentrations are not significantly affected by
subtotal or complete nephrectomy, according to
Maier et al [68]. The increase in ureagenesis ob-
served in liver slices from nephrectomized rats, as
compared with controls, is largely obliterated if or-
nithine or citrulline is added to both groups of liver
slices [69].
In conclusion, several unexplained abnormalities
in the concentrations and distribution of urea cycle
intermediates in uremia have been observed.
(d) Urea genesis in isolated liver. Several studies
[69—72] have established that liver obtained from
acutely uremic animals takes up added amino acids
and produces more urea than does liver from nor-
mal animals. Furthermore, urea production by iso-
lated perfused liver from uremic rats is increased in
the absence of added amino acids [72], indicating an
accelerated rate of proteolysis of perfu sate albumin
or of endogenous tissue proteins.
Associated with these abnormalities is an in-
creased rate of gluconeogenesis from amino acids
seen in isolated perfused liver of uremic animals
[72] (Fig. 4). Increased gluconeogenesis is also seen
in chronically uremic patients. Acidosis itself could
not be responsible. Indeed, reduction of the per-
fusate pH lowers ureagenesis in the perfused liver
[73—75].
Hyperglucagonemia, which is generally seen in
chronic uremic patients [76], could play a role.
Glucagon stimulates ureagenesis [77], evidently by
promoting mitochondrial ATP synthesis [78]. In iso-
lated hepatocytes, glucagon stimulates gluconeo-
genesis from glutamine more than it does from any
other amino acid [79]. Because glutamine uptake by
the hepatosplanchnic bed is reduced in chronic re-
nal failure and also in chronic metabolic acidosis
[80], this explanation for increased gluconeogenesis
may be incorrect. Furthermore, glucagon probably
could not account for the observations cited above
in acutely uremic rats.
(e) Inhibition of hepatic urea genesis by urea. A
profound reduction of urea production by liver
slices on adding urea to the medium has been re-
ported [81], but not as yet confirmed. Arginino-
succinate lyase is, however, inhibited by urea con-
centrations similar to those seen in uremic patients
[82]. Attempts to quantitate argininosuccinate lev-
els in blood or urine of uremic patients or animals
have apparently not been reported.
Lysine, an inhibitor of arginase [83], has been re-
ported to diminish ureagenesis in experimental ani-
mals [84] and also in two patients [85]. Use of this
amino acid to lower blood urea of uremic patients
does not seem promising, as it could only result in
the accumulation of urea precursors.
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Fig. 4. Relationship between gluconeo genesis and ureagenesis in
isolated perfused livers of normal (closed squares), sham-oper-
ated (closed triangles) and uremic (closed circles) rats, exposed
to varying concentrations of amino acids in the perfusate. Livers
from uremic rats take up more amino acids, produce more urea,
and synthesize more glucose than do livers from the nonuremic
animals. The ratio of gluconeogenesis to ureagenesis averages
0.88 and is the same in all three groups. (Reprinted with per-
mission from the authors and Eur J Clin Invest [72])
(2) Relationship between protein (or amino acid)
intake, nitrogen balance, and urea appearance: (a)
Estimation of nitrogen balance from urea appear-
ance. Nitrogen balance can be expressed as nitro-
gen intake (I) minus urea nitrogen appearance (UN)
minus nitrogen excretion (by all routes) in forms
other than urea (NUN), that is,
bN=I-UN-NUN
Because NUN is nearly independent of I, changes
in balance in a given subject can be estimated very
closely from changes in urea nitrogen appearance
and nitrogen intake. The principal uncertainty (as-
suming that protein intake is known) lies in estimat-
ing urea accumulation when the urea pool is chang-
ing. As noted above, sequential measurements over
an interval of nearly a week may be necessary.
Ideally, daily estimates of the urea pool should be
fitted to an exponential function describing the ap-
proach to a steady state [5], but for practical pur-
poses, a linear approximation will generally suffice.
Nitrogen intake, g/day
Fig. 5. Plasma urea nitrogen concentration on different nitrogen
intakes in patients with three different levels of renal function.
Assumptions are that fecal nitrogen plus nonurea urinary nitro-
gen excretion is equal to 2.5 g/day and that nitrogen balance is
equal to zero. (Reprinted with permission of the author and this
journal, Kidney mt [1141)
If the urea pooi is not changing, estimation of urea
appearance merely requires a 24-hr urine collection
for urea determination. An average value for NUN
in uremic patients of average size is 2.5 g!day. Us-
ing these values, a fairly good estimate of nitrogen
balance can be obtained. Obviously, it is important
to consider proteinuria as a factor that may increase
NUN.
(b) Steady-state serum urea nitrogen as a func-
tion of protein intake. If nitrogen balance is as-
sumed to be neutral and NUN is assumed to be in-
dependent of protein intake, the relationship be-
tween nitrogen intake and serum urea nitrogen is a
simple linear one (Fig. 5). The slope of this line de-
pends on urea clearance. The figure illustrates two
important points: (I) serum urea nitrogen levels
above 100 mg/dl should not occur in patients with
fairly severe renal failure unless protein intake is far
above nutritional requirements or unless there is ex-
cessive catabolism and negative nitrogen balance;
(2) small changes in nitrogen intake that do not alter
nitrogen balance may nevertheless induce sub-
stantial changes in serum urea nitrogen in severely
uremic patients.
Rafoth and Onstad [3] have shown that in normal
persons fed beef protein loads, the rate of urea ap-
pearance (which was equal to urea production in
their subjects) is an approximately linear function of
total serum amino nitrogen concentration (Fig. 6).
As noted above, no evidence for approaching satu-
ration of urea synthetic capacity could be detected.
An interesting feature of this relationship is that ex-
trapolation does not appear to go through the origin.
The authors note that this would suggest that urea
production ceases below a serum amino acid nitro-
gen concentration of about 3.5 mg!dl. Results of
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plasma amino acid analysis in infants with complete
urea cycle defects being treated with keto-ana-
logues [86] support this inference.
(c) Uremia in the absence of renal failure. A rela-
tionship similar to the one shown in Fig. 5 can be
derived for subjects with normal renal function, that
is, a urea clearance of approximately 50 mI/mm or
70 liters/day. If 3 g/day is used as an average value
of NUN for normal subjects in nitrogen balance,
then steady-state serum urea nitrogen, expressed in
grams per liter (SSUN), is computed by combining the
urea clearance formula
UNISSUN = 70
and the expression for nitrogen balance given
above, to yield
SSUN = (IN 3)/70
Thus, a serum urea nitrogen of 70 mg/dl or 0.7 glliter
would require a nitrogen intake of 52 g/day, or the
equivalent of 325 g of protein per day. Values close
to these were observed in a normal subject by Rich-
ards and Brown [87]. By subsisting on a diet con-
sisting chiefly of fish and a prepared protein pow-
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Fig. 6. Urea appearance in normal subjects as a function of total
serum a,nino acid nitrogen concentration. Hour-to-hour changes
in urea excretion plus accumulation were measured following
protein loads. Because urea degradation was close to zero in
these subjects, the results give production as well as appearance.
(Reprinted with permission of the authors and J C/in Invest [3])
der, this patient maintained a serum urea nitrogen
of 50 to 80 mgldl for years, while excreting 40 to 50
• g/day of urea nitrogen.
It has been suggested that starvation can induce
azotemia in the absence of renal impairment [88,
89], as indeed it would if comparable quantities of
endogenous protein were catabolized for energy. It
has been repeatedly demonstrated, however, that
starvation in man (in contrast to the rat) reduces
urea excretion, as first glycogen and then fat stores
are mobilized for energy [90]. When fat stores are
depleted, a terminal phase sets in, during which
serum urea nitrogen returns to normal [91]. On the
basis of this information, purported instances of
starvation-induced azotemia have been questioned
[92, 93].
Rarely, a tubular defect causing excessive reab-
sorption of urea may lead to uremia in the absence
of any other demonstrable defect in renal function
C C C C C C C [94].
(d) Role of enzyme adaptation in mediating
changes in urea genesis in response to dietary' nitro-
gen. Schimke [95] demonstrated a coordinated in-
duction of urea cycle enzymes in rats fed diets vary-
ing in protein content. Further work [96] has dem-
onstrated that this adaptive response can occur
within less than a day. As pointed out [97], the re-
sponse of ureagenesis to a protein load is, however,
far more rapid than these changes in enzyme levels.
Saheki, Ohbuko, and Katsunuma [98] recently have
reported that hepatic ornithine and N-acetyl-gluta-
mate concentrations both rise within 15 mm after an
i.p. load of ammonium chloride. Because both sub-
stances promote ureagenesis [52, 99], these obser-
vations indicate that short-term regulatory mecha-
nisms (see Ref. 50) may play an important role in
modulating the rate at which nitrogen loads are
excreted. Whether these mechanisms are impaired
in uremia is not known.
(e) Obligatory tirea nitrogen excretion. The rates
of excretion of nitrogenous waste products in sub-
jects ingesting protein-free diets have traditionally
been considered as obligatory minima [100]. It is
now clear that excretion rates of all of the com-
ponents of nitrogen excretion far lower than these
values can occur. Creatinine excretion (or appear-
ance) in severe renal failure may fall to one third of
the rate observed in normal subjects owing to
creatinine metabolism [101], and uric acid excretion
is similarly reduced [102]. Ammonia excretion is al-
so low [102]. In starvation [1, 90], during prolonged
oral or parenteral feeding of elemental diets [103],
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fecal nitrogen becomes much lower than so-called
"endogenous" fecal nitrogen [100].
The absence of any obligatory ureagenesis is
demonstrated most strikingly in infants with com-
plete defects of one of the first three enzymes of the
urea cycle. Although these children make some
urea, it is evidently derived entirely from dietary ar-
ginine via arginase and therefore does not represent
the excretion of waste nitrogen [66]. Despite com-
plete inability to excrete waste nitrogen as urea,
two of these infants are at present growing normally
on a diet severely restricted in protein, supple-
mented with essential amino acids and their nitro-
gen-free analogues (Walser, Beaudet, and Glasgow,
unpublished observations).
Thus, urea synthesis, itself, is not essential to
life. Negative values for urea appearance could in
theory occur in subjects reutilizing urea nitrogen for
protein synthesis. Although occasional estimates of
negative appearance rates have been reported [104,
105], it remains to be demonstrated that uremic sub-
jects can consistently maintain urea nitrogen ap-
pearance rates below 0.5 g/day.
('3) Release of urea and urea precursors from pe-
ripheral tissues. The major site of urea synthesis is
the liver. Although some evidence has been pre-
sented that the complete urea cycle is found in or-
gans other than the liver, and occasional reports
have suggested that other organs synthesize a sig-
nificant fraction of total urea production, it is gener-
ally agreed that the liver is the only significant site
of urea synthesis. The wide distribution of arginase
in tissues [81] is consistent, however, with the pos-
sibility that some arginine may be hydrolyzed to or-
nithine and urea extrahepatically.
Measurements of net balances of amino acids
across muscle have shown that alanine and gluta-
mine account for more than half of the total amino
nitrogen released [106, 107]. Whether protein syn-
thetic rate in muscle of uremic animals is normal
[108] or subnormal [109] is controversial. Garber,
Karl, and Kipnis [110] recently reported that ala-
nine and glutamine release from muscle of uremic
rats was increased. Insulin inhibited release of these
amino acids more than it did in control rat muscle.
These results contrast with the findings of Mondon,
Dulkes, and Reaven [111], who observed dimin-
ished insulin responsiveness in the muscle of ure-
mic rats.
Garber et al [110] also found that epinephrine or
serotonin inhibited alanine and glutamine release by
normal muscle, but not by uremic muscle. Evidence
was presented for a defect in cyclic AMP produc-
tion by uremic muscle.
Mitch and Chan [112] recently have reported in
preliminary form that bilateral ureteral ligation in
rats produces an augmentation in amino acid re-
lease from isolated perfused muscle that is not at-
tributable chiefly to alanine and glutamine.
Thus, a variety of abnormalities have been dem-
onstrated in peripheral release of amino acids in
acutely uremic rats. Whether these findings are ap-
plicable to chronically uremic man is uncertain.
Evidence supporting abnormally high protein cata-
bolic rates, as well as evidence indicating better
than normal capacity to conserve nitrogen, has
been reported [113]. Because, as noted above,
NUN tends to be subnormal in uremia (in the ab-
sence of proteinuria), any tendency to excessive ni-
trogen wastage is almost certainly manifested by in-
creased urea appearance, whether derived from ab-
normal peripheral release of urea precursors,
excessive hepatic conversion of such precursors to
urea, or both.
Sununarv
The absolute rate at which urea is degraded by
bacterial urease in the gastrointestinal tract in
chronic uremia is not different from normal, al-
though the fraction of synthesized urea degraded is
high. Urea production is therefore comprised of two
portions, urea derived from enterohepatic circula-
tion of urea nitrogen and the urea that serves to
eliminate excess labile nitrogen. This latter quanti-
ty, termed urea appearance, is defined as excretion
plus accumulation of urea in body fluids, and can be
estimated by measurements of body weight and
serum urea nitrogen concentration. The importance
of urea appearance is that nitrogen balance in
chronic uremia can be estimated as the difference
between nitrogen intake and urea appearance, plus
an average rate of 2.5 g of nitrogen per day for ex-
cretion of nitrogen in forms other than urea.
Regulation of ureagenesis in normal subjects and
in uremic subjects is chiefly a function of the sys-
temic concentration of urea precursors (amino
acids). Rapid activation of ureagenesis occurs after
amino acid loads of 0.5 to 2 g/kg, mediated by N-
acetyl glutamate, an activator of mitochondrial car-
bamyl phosphate synthetase. The rapid rise in N-
acetyl glutamate is apparently secondary to a rapid
increase in liver glutamate, thereby promoting N-
acetyl glutamate synthesis by a substrate effect.
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No clear evidence for significant enzymatic ab-
normalities in uremic liver has been found. Never-
theless, the acutely uremic liver converts amino
acids to urea at an abnormally high rate. Further-
more, acute uremia augments the peripheral release
of amino acids, especially from muscle. This sug-
gests that loss of renal function increases urea pro-
duction by an unknown mechanism.
Demonstration that the virtual absence of urea
production need not impair growth and that urea ap-
pearance can be lowered by nutritional means sug-
gests that nitrogen balance could be safely main-
tained at extremely low rates of urea appearance.
The development of new methods to achieve this
goal may prove useful in uremia and other disorders
characterized by protein intolerance.
MACKENZIE WALSER
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